MannKind Corporation Company Profile (NASDAQ:MNKD)

About MannKind Corporation (NASDAQ:MNKD)

MannKind Corporation logoMannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MNKD
  • CUSIP: 56400P20
  • Web:
  • Market Cap: $606.53 million
  • Outstanding Shares: 114,874,000
Average Prices:
  • 50 Day Moving Avg: $2.80
  • 200 Day Moving Avg: $1.67
  • 52 Week Range: $0.67 - $6.96
  • Trailing P/E Ratio: 4.08
  • Foreward P/E Ratio: -6.35
  • P/E Growth: -0.21
Sales & Book Value:
  • Annual Revenue: $179.93 million
  • Price / Sales: 3.45
  • Book Value: ($2.12) per share
  • Price / Book: -2.55
  • EBITDA: $60.33 million
  • Net Margins: 71.60%
  • Return on Equity: -24.93%
  • Return on Assets: 57.11%
  • Debt-to-Equity Ratio: -0.48%
  • Current Ratio: 0.59%
  • Quick Ratio: 0.56%
  • Average Volume: 6.62 million shs.
  • Beta: 3.16
  • Short Ratio: 13.18

Frequently Asked Questions for MannKind Corporation (NASDAQ:MNKD)

What is MannKind Corporation's stock symbol?

MannKind Corporation trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind Corporation's earnings last quarter?

MannKind Corporation (NASDAQ:MNKD) released its quarterly earnings data on Monday, August, 7th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.10. The business had revenue of $2.16 million for the quarter, compared to the consensus estimate of $2.75 million. MannKind Corporation had a negative return on equity of 24.93% and a net margin of 71.60%. During the same period in the previous year, the business posted $0.08 earnings per share. View MannKind Corporation's Earnings History.

When will MannKind Corporation make its next earnings announcement?

MannKind Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for MannKind Corporation.

Where is MannKind Corporation's stock going? Where will MannKind Corporation's stock price be in 2017?

4 equities research analysts have issued 1-year price targets for MannKind Corporation's stock. Their predictions range from $0.83 to $1.00. On average, they expect MannKind Corporation's share price to reach $0.92 in the next year. View Analyst Ratings for MannKind Corporation.

Are investors shorting MannKind Corporation?

MannKind Corporation saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 23,218,074 shares, an increase of 9.8% from the August 31st total of 21,137,769 shares. Based on an average daily volume of 4,030,516 shares, the short-interest ratio is presently 5.8 days. Approximately 36.2% of the company's stock are short sold.

Who are some of MannKind Corporation's key competitors?

Who are MannKind Corporation's key executives?

MannKind Corporation's management team includes the folowing people:

  • Kent Kresa, Chairman of the Board
  • Michael E. Castagna Pharm.D., Chief Executive Officer, Director
  • Rosabel R. Alinaya, Acting Chief Financial Officer, Senior Vice President, Chief Accounting Officer
  • Steven B Binder, Chief Financial Officer, Principal Accounting Officer
  • Linda Adreveno, Senior Vice President - Human Resources
  • Joseph Kocinsky, Chief Technology Officer, Corporate Vice President
  • David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary
  • Patrick McCauley J.D., Chief Commercial Officer
  • Stuart A. Tross Ph.D., Chief People Officer
  • James Samuel Shannon M.D., Director

How do I buy MannKind Corporation stock?

Shares of MannKind Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind Corporation's stock price today?

One share of MannKind Corporation stock can currently be purchased for approximately $5.40.

MarketBeat Community Rating for MannKind Corporation (NASDAQ MNKD)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  305 (Vote Underperform)
Total Votes:  522
MarketBeat's community ratings are surveys of what our community members think about MannKind Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for MannKind Corporation (NASDAQ:MNKD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Sell Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $0.92 (83.06% downside)
Consensus Price Target History for MannKind Corporation (NASDAQ:MNKD)
Price Target History for MannKind Corporation (NASDAQ:MNKD)
Analysts' Ratings History for MannKind Corporation (NASDAQ:MNKD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/10/2017HC WainwrightInitiated CoverageBuy -> BuyN/AView Rating Details
9/1/2017Maxim GroupReiterated RatingBuyHighView Rating Details
5/22/2017J P Morgan Chase & CoReiterated RatingUnderweightHighView Rating Details
5/11/2017Piper Jaffray CompaniesSet Price TargetSell$1.00MediumView Rating Details
5/8/2017S&P Equity ResearchLower Price Target$1.04 -> $0.83HighView Rating Details
6/1/2016Royal Bank Of CanadaLower Price TargetUnderperform$1.00 -> $0.15N/AView Rating Details
4/28/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
4/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingSellN/AView Rating Details
1/6/2016Griffin SecuritiesUpgradeNeutral -> Buy$4.00N/AView Rating Details
11/14/2015Jefferies Group LLCReiterated RatingBuy$9.00N/AView Rating Details
(Data available from 10/17/2015 forward)


Earnings History for MannKind Corporation (NASDAQ:MNKD)
Earnings by Quarter for MannKind Corporation (NASDAQ:MNKD)
Earnings History by Quarter for MannKind Corporation (NASDAQ MNKD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/7/2017Q2 2017($0.25)($0.35)$2.75 million$2.16 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.09)($0.17)$3.50 million$3.00 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.20)($0.19)$6.00 million$12.40 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.06)$0.26$2.00 million$162.35 millionViewListenView Earnings Details
8/8/2016Q2($0.06)($0.07)$0.03 millionViewN/AView Earnings Details
5/9/2016Q116($0.04)($0.06)ViewN/AView Earnings Details
3/14/2016Q4($0.05)($0.66)$0.35 millionViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.08)ViewN/AView Earnings Details
8/10/2015Q215($0.08)($0.07)$0.53 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.08)$5.40 millionViewListenView Earnings Details
2/24/2015Q414($0.09)($0.09)$3.13 millionViewListenView Earnings Details
11/3/2014Q314$0.09($0.09)$66.60 millionViewListenView Earnings Details
8/11/2014Q214($0.11)($0.19)ViewListenView Earnings Details
5/12/2014Q114($0.13)($0.14)ViewListenView Earnings Details
2/18/2014Q4($0.14)($0.16)$0.43 millionViewListenView Earnings Details
11/4/2013Q313($0.14)($0.17)ViewListenView Earnings Details
8/9/2013Q2 2013($0.14)($0.16)ViewN/AView Earnings Details
5/9/2013Q1 2013($0.15)($0.15)ViewListenView Earnings Details
2/11/2013Q4 2012($0.19)($0.23)ViewListenView Earnings Details
11/1/2012Q312($0.24)($0.22)ViewN/AView Earnings Details
8/7/2012($0.24)($0.23)ViewN/AView Earnings Details
5/9/2012($0.23)($0.27)ViewN/AView Earnings Details
2/22/2012($0.32)($0.30)ViewN/AView Earnings Details
11/3/2011($0.32)($0.31)ViewN/AView Earnings Details
8/4/2011($0.30)($0.37)ViewN/AView Earnings Details
5/9/2011($0.29)($0.34)ViewN/AView Earnings Details
2/10/2011($0.40)($0.33)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for MannKind Corporation (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-1.04 EPS
Next Year EPS Consensus Estimate: $-0.85 EPS


Dividend History for MannKind Corporation (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for MannKind Corporation (NASDAQ:MNKD)
Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 15.67%
Insider Trades by Quarter for MannKind Corporation (NASDAQ:MNKD)
Institutional Ownership by Quarter for MannKind Corporation (NASDAQ:MNKD)
Insider Trades by Quarter for MannKind Corporation (NASDAQ:MNKD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/13/2017Kent KresaDirectorBuy166,600$6.00$999,600.00View SEC Filing  
8/10/2017Raymond W UrbanskiCMOSell296$1.15$340.40View SEC Filing  
6/30/2017Rosabel Realica AlinayaSVPBuy2,000$1.23$2,460.00View SEC Filing  
1/3/2017Matthew J PfefferCEOBuy4,540$0.54$2,451.60View SEC Filing  
1/3/2017Rosabel Realica AlinayaSVPBuy9,043$0.54$4,883.22View SEC Filing  
8/26/2016Michael CastagnaInsiderBuy17,500$0.78$13,650.00View SEC Filing  
8/24/2016Michael CastagnaInsiderBuy15,000$0.87$13,050.00View SEC Filing  
8/23/2016Michael CastagnaInsiderBuy25,000$0.94$23,500.00View SEC Filing  
8/15/2016Matthew J PfefferCEOBuy25,000$0.99$24,750.00View SEC Filing  
8/12/2016Michael CastagnaInsiderBuy25,000$1.00$25,000.00View SEC Filing  
5/17/2016Michael CastagnaInsiderBuy50,000$0.93$46,500.00View SEC Filing  
4/24/2015Hakan EdstromCEOSell73,460$4.83$354,811.80View SEC Filing  
3/27/2015Hakan EdstromCEOSell73,460$5.21$382,726.60View SEC Filing  
2/10/2015Hakan EdstromCEOSell73,460$7.75$569,315.00View SEC Filing  
2/5/2015David ThomsonVPSell80,000$7.00$560,000.00View SEC Filing  
1/5/2015Diane PalumboVPSell188,999$5.95$1,124,544.05View SEC Filing  
11/24/2014David ThomsonVPSell118,114$6.14$725,219.96View SEC Filing  
10/3/2014Juergen MartensVPSell63,800$5.48$349,624.00View SEC Filing  
8/27/2014Juergen MartensVPSell417$7.60$3,169.20View SEC Filing  
8/7/2014David ThomsonVPSell30,000$8.16$244,800.00View SEC Filing  
7/21/2014Juergen MartensVPSell26,458$9.65$255,319.70View SEC Filing  
7/15/2014Diane PalumboVPSell17,901$10.01$179,189.01View SEC Filing  
7/1/2014Matthew J PfefferCFOSell20,000$10.44$208,800.00View SEC Filing  
6/30/2014Hakan EdstromCOOBuy1,692$4.42$7,478.64View SEC Filing  
6/27/2014Juergen MartensVPSell25,417$10.53$267,641.01View SEC Filing  
6/26/2014David ThomsonVPSell30,000$10.51$315,300.00View SEC Filing  
6/20/2014Juergen MartensVPSell1,458$10.34$15,075.72View SEC Filing  
6/16/2014Diane PalumboVPSell17,902$10.59$189,582.18View SEC Filing  
6/5/2014Juergen MartensVPSell120,000$11.00$1,320,000.00View SEC Filing  
6/4/2014David ThomsonVPSell133,000$9.95$1,323,350.00View SEC Filing  
6/3/2014Diane PalumboVPSell52,957$9.50$503,091.50View SEC Filing  
5/23/2014Juergen MartensVPSell25,000$7.65$191,250.00View SEC Filing  
5/19/2014Juergen MartensVPSell76,899$7.50$576,742.50View SEC Filing  
5/15/2014Diane PalumboVPSell18,176$7.06$128,322.56View SEC Filing  
1/24/2014Juergen MartensVPSell50,000$5.56$278,000.00View SEC Filing  
12/31/2013Hakan EdstromCOOBuy1,589$4.53$7,198.17View SEC Filing  
12/20/2013Juergen MartensVPSell32,054$5.00$160,270.00View SEC Filing  
12/11/2013David ThomsonVPSell150,000$5.00$750,000.00View SEC Filing  
11/29/2013Juergen MartensVPSell48,057$5.01$240,765.57View SEC Filing  
11/15/2013Diane PalumboVPSell25,000$5.02$125,500.00View SEC Filing  
8/28/2013David ThomsonVPSell19,204$5.78$110,999.12View SEC Filing  
8/26/2013Juergen MartensVPSell20,000$5.52$110,400.00View SEC Filing  
8/1/2013Matthew J PfefferCFOSell10,000$8.00$80,000.00View SEC Filing  
7/2/2013Matthew J PfefferCFOSell10,000$7.00$70,000.00View SEC Filing  
6/30/2013Diane PalumboVPBuy1,610$1.96$3,155.60View SEC Filing  
6/30/2013Matthew J PfefferCFOBuy7,448$1.96$14,598.08View SEC Filing  
6/3/2013Diane PalumboVPSell66,849$7.50$501,367.50View SEC Filing  
5/16/2013Diane PalumboVPSell26,829$5.25$140,852.25View SEC Filing  
5/15/2013Matthew J PfefferCFOSell10,000$5.00$50,000.00View SEC Filing  
12/31/2012Matthew J PfefferCFOBuy1,056$1.95$2,059.20View SEC Filing  
12/21/2012Alfred E MannMajor ShareholderBuy40,000,000$2.59$103,600,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for MannKind Corporation (NASDAQ:MNKD)
Latest Headlines for MannKind Corporation (NASDAQ:MNKD)
DateHeadline logoMonday 10/16 Insider Buying Report: MNKD, PZG - Nasdaq - October 16 at 11:15 PM logoMannKind - Script Sales Dip To Start Q4 - Seeking Alpha - October 16 at 11:15 PM logoMannKind, New Labeling Approved by FDA, Recent Analysts Price Targets - October 16 at 11:15 PM logoKent Kresa Purchases 166,600 Shares of MannKind Corporation (MNKD) Stock - October 13 at 7:42 PM logoMannKind: Bull Case Outweighs Downside Risk - Seeking Alpha - Seeking Alpha - October 13 at 6:54 AM logoMannKind Donates Afrezza® to Support People with Diabetes Impacted by Hurricane Maria in Puerto Rico - October 13 at 6:54 AM logoMannKind (MNKD) Announces 10.17M Share Registered Direct Common Offering at $6/Sh - October 12 at 7:00 AM logoMannKind's stock tumbles after share offering, in wake of recent tripling in price - October 12 at 7:00 AM logoWhy Rite Aid, MannKind, and Sears Holdings Slumped Today - October 12 at 7:00 AM logo7 Essential Rules for Investing in Biotech Stocks - October 12 at 7:00 AM logoShould You Buy the Dip With MannKind Stock? - October 12 at 7:00 AM logoIs MannKind Corp Finally a Buy? - October 11 at 1:17 PM logoWhy MannKind Corporation Dropped a Day After It Ran Up - October 11 at 1:17 PM logoA Deep Dive Into MannKind's Big Bet On Afrezza - October 11 at 12:28 PM logoBRIEF-MannKind announces $61 mln direct offering of stock - October 11 at 4:55 AM logoMannKind Announces $61 Million Registered Direct Offering of Common Stock - October 11 at 4:55 AM logoANAB Makes A Clean Sweep, PTIE Making Gains, Giant Leap By MNKD - October 10 at 11:52 PM logo[$$] MannKind Stock Seen Reaching $7 - October 10 at 11:52 PM logoWhy MannKind, Nutanix, and Smith & Nephew Jumped Today - October 10 at 11:52 PM logoWhy MannKind Corporation Stock Is Jumping Today - October 10 at 12:52 PM logoNew Label For Afrezza Could Turn Things Around At MannKind - October 10 at 11:38 AM logoHC Wainwright Begins Coverage on MannKind Corporation (MNKD) - October 10 at 9:14 AM logoMannKind Corporation (MNKD) Given Average Recommendation of "Hold" by Analysts - October 10 at 8:48 AM logoMark Hulbert: Why a top investment newsletter is betting big on this one stock - October 10 at 5:42 AM logoMannKind - Afrezza Sales Rise Along With Stock Price - Seeking Alpha - October 9 at 3:20 PM logoWhat A Week For MannKind - October 8 at 7:07 PM logoMannKind's stock rockets on heavy volume for third-straight session - October 7 at 6:13 AM logoMannKind Corporation Sees Unusually Large Options Volume (MNKD) - October 7 at 1:02 AM logoTraders Purchase High Volume of MannKind Corporation Put Options (MNKD) - October 7 at 1:02 AM logoPre-Market Most Active for Oct 6, 2017 : NLY, SNCR, IMGN, BAC, MNKD, QQQ, ERIC, TVIX, AZN, BTI, SNY, BABA - Nasdaq - October 6 at 10:41 AM logoMannKind's stock rockets on heavy volume for third-straight session - MarketWatch - October 6 at 10:41 AM logoFriday's Vital Data: MannKind Corporation (MNKD), Apple Inc. (AAPL) and Netflix, Inc. (NFLX) - - October 6 at 10:41 AM logoIs MannKind Corporation Stock Still a Strong Buy? - October 5 at 6:22 PM logoMannKind rally continues, shares up 40% - October 5 at 11:49 AM logoMannKind: Bullish After FDA Label Changes - Seeking Alpha - October 4 at 8:33 AM logoMannKind (MNKD) in Focus: Stock Moves 7.8% Higher - October 4 at 8:33 AM logoCorporate News Blog - MannKind Announces Afrezza Updates from FDA; Includes New Data on Rapid Onset of Activity and Effect Duration - October 4 at 8:33 AM logoToday's Research Reports on Stocks to Watch: Mannkind and EnteroMedics - October 4 at 8:33 AM logoMannKind Corporation to Hold Investor Conference Call - GlobeNewswire (press release) - October 2 at 10:32 PM logoWhy MannKind Corporation Popped Today - October 2 at 5:30 PM logoWhy MannKind Stock Started October With a Bang - October 2 at 3:24 PM logoMannKind Corporation (MNKD) Earns "Buy" Rating from Maxim Group - October 2 at 1:20 PM logoMannKind: FDA OKs Update To Afrezza Prescribing Information To Add New Data - October 2 at 11:46 AM logoForm 8-K MANNKIND CORP For: Sep 29 - October 2 at 11:46 AM logoBRIEF-Mannkind Corp says FDA updates Afrezza prescribing information - October 2 at 11:45 AM logoFDA Updates Afrezza® Prescribing Information - October 2 at 11:45 AM logo3 Biotech Stocks That Are Trending Pre-Market On Monday - October 2 at 11:45 AM logoMannKind ahead 9% premarket on Afrezza label update - October 2 at 8:19 AM logoMannKind Corporation to Hold Investor Conference Call - October 1 at 5:47 PM logoToday's Research Reports on Trending Tickers: MannKind Corporation and Spectrum Pharmaceuticals - September 29 at 1:28 PM



MannKind Corporation (MNKD) Chart for Tuesday, October, 17, 2017

This page was last updated on 10/17/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.